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Abstract 
Plasma cholesterol level is controlled by various factors. In the present study, high plasma ctivity of cholesterol esterase was found to 
correlate with plasma total cholesterol and low density lipoprotein (LDL) cholesterol levels in normolipidemic human subjects. However, 
the cholesterol esterase is not elevated in plasma of patients with familial hypercholesterolemia. These observations suggest hat 
cholesterol esterase level is not determined by plasma cholesterol level, but elevated cholesterol esterase may be causative in increasing 
plasma cholesterol and LDL. Additional experiments further demonstrated that cholesterol esterase can convert the larger and 
less-atherogenic LDL to the smaller and more atherogenic LDL subspecies in vitro. These results uggest that plasma cholesterol esterase 
contributes to the formation and accumulation of atherogenic lipoproteins, and thus is a major isk factor for premature atherosclerosis in 
normal human subjects. 
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Coronary heart disease is the leading cause of death in 
the Western world. This is a complex disorder involving 
many genetic and environmental factors [1-3]. A major 
risk factor associated with this disease is the elevated 
levels of total cholesterol and low density lipoprotein 
(LDL) cholesterol in plasma [4]. The most widely charac- 
terized genetic influence on LDL level is the abnormality 
associated with LDL receptor defects [5]. Mutations in the 
apolipoprotein B-100 gene have also been shown to affect 
LDL catabolism resulting in accumulation of LDL in 
plasma [6-9]. However, defective LDL receptor gene af- 
fects 1 in 500 individuals and the prevalence of defective 
apolipoprotein B-100 was estimated to be 0.2% [9-11]. 
Therefore, these rare genetic diseases cannot account for 
most of the variations in LDL level among the general 
population. Additional factors may also be involved in 
controlling LDL homeostasis. 
Recent studies suggested that LDL particle size is an 
important risk factor for atherosclerosis. The results were 
supported by observations of association between individu- 
als with predominantly small, dense LDL particles and 
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their risk of premature atherosclerosis [12-14]. Based on 
LDL sizing by nondenaturing gradient gel electrophoresis, 
two distinct LDL subclass phenotypes have been described 
[ 13,15]. The LDL subclass phenotype B, characterized by a 
predominance of small LDL particles, is present in approx. 
30% of the general population and is associated with 
increased risk of atherosclerosis [ 14,15]. 
Despite the current intense focus on understanding LDL 
metabolism and the identification of LDL size as a major 
risk factor for atherosclerosis, the enzyme(s) responsible 
for dictating LDL phenotype and atherosclerosis suscepti- 
bility has not been identified to date. The study by Zambon 
et al. showed an inverse relationship between hepatic 
lipase activity with LDL particle size [16]. However, hep- 
atic lipase activity was found to be similar between ormo- 
lipidemic subjects and coronary artery disease patients 
[16]. Although the importance of hepatic lipase as a risk 
factor for atherosclerosis remains uncertain, these results 
suggest hat LDL phenotype may be dictated by lipolytic 
enzymes that can alter the lipid composition of lipopro- 
teins. 
Recently, the pancreatic cholesterol esterase, also called 
carboxyl ester lipase or bile salt stimulated lipase, has been 
shown to be synthesized and secreted into plasma by the 
liver [17-21]. Since this protein is a lipolytic enzyme with 
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Table 1 
Cholesterol esterase activity in human plasma of different normo- 
lipidemic human subjects 
Subjects Gender Experiments Cholesterol esterase activity 
[(pmol/h ng protein) x 10 ~s ] 
1 F A 4.20 
B 4.24 
2 M A 5.43 
B 7.62 
3 F A 3.00 
B 2.29 
4 M A 8.12 
B 7.94 
C 8.14 
5 F A 4.16 
B 5.46 
Experiments A, B, and C indicated the samples were obtained at different 
days. Cholesterol esterase activity was measured based on the hydrolysis 
of cholesteryl [ 14 C]oleate. The data represented three separate determina- 
tions. 
wide substrate specificity [reviewed in [22]], the choles- 
terol esterase in plasma may alter lipid content and change 
the surface-to-core lipid distribution and size of lipopro- 
teins. The purpose of this investigation is to ascertain the 
possible correlation between plasma cholesterol esterase 
activity with cholesterol level and its effect on LDL parti- 
cle size. 
Initial experiments were performed to verify the pres- 
ence of cholesterol esterase activity in human plasma. In 
these experiments, lipoprotein-free plasma were used to 
avoid possible lipoprotein interference of the in vitro as- 
say. The results showed that consistent cholesterol esterase 
activity could be obtained from different sampling of the 
same subject if blood was drawn in the morning after an 
overnight fast (Table 1). These results indicated that poten- 
tial variations in cholesterol esterase activity among vari- 
ous plasma samples [17] were not due to variability in the 
assay and were probably due to individual variations in the 
plasma level of cholesterol esterase. 
The possible influence of cholesterol esterase in 
lipoprotein levels in human subjects was investigated by 
comparing plasma cholesterol and lipoprotein levels with 
the level of cholesterol esterase activity present in each 
sample. Thirty healthy human volunteers, ages 19-45, 
were recruited for the initial determination. The nature and 
consequence of the study were explained to the volunteers 
and informed consent was obtained. The subjects were of 
both genders with 57% male and 43% female. All donors 
were fasted overnight for at least 14 h until blood was 
drawn at 9 a.m. An aliquot of each plasma sample was 
used for cholesterol and lipoprotein determinations while 
0.6 ml of each plasma sample was centrifuged at d = 1.21 
g /ml  to prepare lipoprotein deficient plasma. The choles- 
terol esterase was found exclusively in the lipoprotein 
deficient plasma and no enzyme was associated with lipo- 
proteins after ultracentrifugation. Therefore, the lipoprotein 
deficient plasma at the d > 1.21 g /ml  fraction was used 
for all cholesterol esterase activity measurements. The 
results, as shown in Fig. 1, revealed a significant correla- 
tion between bile salt-stimulated cholesterol esterase activ- 
ity and cholesterol level in plasma (r  = 0.694, p = .0001). 
The elevated cholesterol esterase level may be a result 
of increased plasma cholesterol concentration. Alterna- 
tively, elevated level of cholesterol esterase may be a 
causal factor and contributes to plasma cholesterol home- 
ostasis in human subjects. These possibilities were investi- 
gated by examining the plasma cholesterol esterase activity 
in two homozygous familial hypercholesterolemic subjects. 
The results showed that, despite the severe elevation in 
their plasma cholesterol evels, due to defects in LDL 
receptor function, the cholesterol esterase levels in these 
subjects were similar to those observed with healthy indi- 
viduals (Fig. 1). This observation contradicts the first 
hypothesis and suggests the exciting possibility that high 
level of plasma cholesterol esterase activity, at least in 
normolipidemic and moderately hyperlipidemic subjects, 
may contribute to a higher steady state cholesterol level in 
human plasma. 
The relationship between plasma cholesterol and choles- 
terol esterase activity was further explored by determining 
the relationship between cholesterol esterase activity with 
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Fig. 1. Correlation of human plasma cholesterol levels with cholesterol 
esterase activity in 30 healthy donors (open circles) and two homozygous 
Type II familial hypercholesterolemic patients (filled circles). Total plasma 
cholesterol was determined by a hydrolase/oxidase colorimetric method 
in a Hitachi 717. Lipoprotein deficient plasma, prepared by ultracentrifu- 
gation at d> 1.21 g/ml ,  were used to determine cholesterol esterase 
activity. The reaction mixture containing 50 mM Tris-HCl (pH 7.5), 33 
mM cholate, and 1.96 nmol of cholesteryl [14C]oleate. The samples were 
incubated for 1 hr at 37°C. The reaction was terminated by adding 3.25 
ml of methanol/chloroform/heptane (1.41:1.25:1.0; v /v /v )  and 1.05 ml 
of 50 mM sodium carbonate and 50 mM sodium borate (pH 10). After 
centrifugation of the samples for 35 min at 1500x g, 500 kd of the 
aqueous fraction was removed for liquid scintillation counting. Choles- 
terol esterase activity was determined based on the appearance of 
[ 14 C]oleate. The correlation of plasma cholesterol with bile salt-activated 
cholesterol esterase activity in the plasma of normolipidemic ndividuals 
was analyzed by linear regression. 
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Fig. 2. Correlation of plasma cholesterol esterase activity with LDL- 
cholesterol (A) and HDL-cholesterol (B) levels in normal human subjects. 
Lipoprotein deficient plasma from 30 healthy donors (open triangles) 
were used to determine cholesterol esterase activity, based on the hydrol- 
ysis of cholesteryl [t4C]oleate. The level of HDL-cholesterol was deter- 
mined after phosphotungstate/MgCI 2 precipitation and centrifugation to
remove the LDL and VLDL. The level of LDL-cholesterol was calculated 
using the Friedenwald equation: [LDL-Cholesterol]= [Total Cholesterol] 
-[HDL-Cholesterol]- [VLDL-Cholesterol], where [VLDL-Cholesterol] is
estimated by [triglyceride]/5. 
LDL and HDL levels. In these experiments, ubjects with 
known genetic defects in the lipoprotein metabolic path- 
way, such as the Type II familial hypercholesterolemic 
patients, were excluded and only healthy normolipidemic 
volunteers were tested. A positive correlation was ob- 
served between cholesterol esterase activity with plasma 
LDL level (r  = 0.600, p < 0.001) (Fig. 2A). However, the 
relationship between plasma cholesterol esterase and HDL 
level was not statistically significant (Fig. 2B). 
Additional experiments were performed to ascertain the 
possibility that plasma cholesterol esterase level may be a 
contributing factor in determining LDL particle size. Two 
separate preparations of LDL were incubated with or 
without purified cholesterol esterase in vitro using the 
Table 2 
Lipid composition of control and cholesterol esterase-hydrolyzed LDL 
Lipid Control LDL CEase-LDL 
(mg/mg protein) (rag/rag protein) 
Free cholesterol 0.45 + 0.11 0.70 + 0.15 
Cholesteryl esters 1.50 ± 0.33 1.20 ± 0.40 
Phospholipids 1.00 ± 0.15 0.95 ± 0.20 
Triglycerides 0.20 ± 0.08 0.17 ± 0.10 
procedure described by Aviram et al. [23]. Because bile 
salt concentration i  plasma is below that required for 
cholesterol esterase stimulation, these experiments were 
performed in the absence of bile salt to mimic the physio- 
logic environment. The samples were then applied to 
nondenaturing radient gel electrophoresis for analysis. 
The results indicated that, after 1 h of incubation, the 
purified cholesterol esterase converted most of the larger 
LDL subfractions to the smaller LDL species (Fig. 3). 
Prolonged incubation of LDL with cholesterol esterase 
resulted in the complete conversion of large LDL to small 
LDL particles. These small LDL appeared to be the end 
product of cholesterol esterase-hydrolyzed LDL, since 
lipoproteins maller than 23 nm were not observed. 
The mechanism of cholesterol esterase induced changes 
in LDL size was investigated by determining lipid compo- 
sition of the LDL before and after incubation with choles- 
terol esterase or with a mutagenized inactive enzyme 
[24,25]. A consistent decrease in LDL cholesteryl ester, 
with concomitant increase in free cholesterol, was ob- 
served after treatment with native cholesterol esterase. In 
three separate determinations u ing different LDL prepara- 
tions, the ratio of cholesteryl ester to free cholesterol in the 
LDL changed from an average of 3.33 to 1.70 after 
LDL - A 
LDL - A 
+ CEase ,A 
LDL - 13 
LDL - B 
+ CEase 
Fig. 3. Effects of cholesterol esterase on LDL subfractions. The LDL fraction (d = 1.019-1.063 g/ml)  was isolated from plasma of two subjects. 
Cholesterol esterase was purified from rat pancreas as described (25). The LDL (30 /~g protein) were incubated with (bottom panels) or without (top 
panels) 3 ~g of cholesterol esterase for 1 h at 37°C. Six /xg of LDL protein from Subject 1 and 30 ~g of LDL protein from subject 2 were electrophoresed 
overnight in a 2-16% nondenaturing gradient polyacrylamide gel. The gel was stained with Coomassie brilliant blue R-250 and destained with 
methanol/acetic a id. The LDL phenotype was determined by scanning from the top (left margin) to the bottom (right margin) of the gel. The LDL 
particle sizes were determined by comparison with a standard curve composed of apoferritin (12.2 nm), thyroglobulin (17 nm), and carboxylated latex 
beads (38.1 nm). 
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treatment with the native enzyme (Table 2). However, 
phospholipid and trig]yceride contents in the LDL re- 
mained essentially unchanged after incubation with the 
active cholesterol esterase. Incubation of LDL with the 
inactive His 435--> Gln 435 mutant form of cholesterol es- 
terase [24,25] did not change the lipid composition of the 
LDL nor altered its electrophoretic mobility on nondena- 
turing gradient gels (data not shown). Thus, the cholesterol 
esterase-induced alteration in LDL particle size requires 
hydrolytic activity of the enzyme and is unrelated to the 
lipid transfer properties of cholesterol esterase [26]. The 
effect of cholesterol esterase on LDL particle size is most 
likely due to its ability to alter the composition of surface 
and core components of the lipoprotein. Alternatively, free 
fatty acids generated from cholesterol esterase hydrolysis 
of the cholesteryl esters may also alter the size of the 
lipoprotein. 
Regardless of the precise mechanism for cholesterol 
esterase induced change in LDL particle size, the ability of 
cholesterol esterase to convert large LDL particles to their 
smaller counterparts i provocative. Recent studies have 
demonstrated that LDL particles are biochemically hetero- 
geneous in size and composition [27]. The heterogeneity in 
LDL can be separated into two distinct phenotypes, de- 
noted A and B, based on gradient gel electrophoresis. 
Subjects with phenotype A is characterized by a prepon- 
derance of large LDL particles while subjects with the B 
phenotype is characterized by a preponderance of smaller 
LDL [reviewed in [28]]. The LDL phenotype B has been 
linked to an increased risk of coronary heart disease [28]. 
Therefore, the ability of cholesterol esterase to convert 
large LDL to smaller LDL subspecies, and the relationship 
between plasma cholesterol esterase and LDL levels, sug- 
gest that plasma cholesterol esterase level may be a poten- 
tial risk factor for atherosclerosis. Although the precise 
mechanism by which elevated cholesterol esterase leads to 
LDL accumulation i plasma remains unknown, it is possi- 
ble that the cholesterol esterase may facilitate the conver- 
sion of VLDL and IDL particles to LDL. The ability of 
cholesterol esterase to hydrolyze large lipoproteins to their 
smaller counterparts is consistent with this hypothesis. 
Alternatively, cholesterol esterase may also inhibit LDL 
clearance from circulation. The latter hypothesis is sup- 
ported by a report demonstrating reduced cellular uptake 
of LDL after its hydrolysis by bacterial cholesterol esterase 
[23]. Regardless of the mechanism of cholesterol esterase 
induced LDL accumulation, this study points to the possi- 
bility of using plasma cholesterol esterase level measure- 
ment as a diagnostic marker for early identification of 
subjects at risk for premature atherosclerosis. Inhibitors for 
cholesterol esterase may also be employed as a therapeutic 
intervention strategy to reduce the risk of coronary heart 
disease. Additional detailed studies exploring the relation- 
ship between cholesterol esterase genotype with plasma 
cholesterol and LDL level, and their mode of inheritance 
of these traits, are also warranted. 
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